prospectus is                     , 2015.Table of ContentsTransforming Lives with Safer, More Effective TherapiesTable of ContentsTABLE OF CONTENTSExplanatory NoteiAbout This ProspectusiiProspectus Summary1The Offering8Summary Financial and Other Data10Risk Factors12Special Note Regarding Forward-Looking Statements50Statistical Data and Market Information52Use of Proceeds53Dividend Policy55Capitalization56Dilution58Selected Historical Financial Information and Other Data61Management’s Discussion and Analysis of Financial Condition and Results of Operations63Business77Management121Executive and Director Compensation131Certain Relationships and Related Party Transactions141Principal Stockholders145Description of Capital Stock149Shares Eligible for Future Sale154Material U.S. Federal Tax Consequences for Non-U.S. Holders of Common Stock157Underwriting160Legal Matters168Experts168Where You Can Find Additional Information168Explanatory NoteUnless we state otherwise or the context otherwise requires, references in this prospectus to:•“we,” “our,” “us,” “our company” and “CytomX” refer to CytomX Therapeutics, Inc.;•the “FDA” refer to the U.S. Food and Drug Administration;•“preferred stock” refer to our redeemable convertible preferred stock and convertible preferred stock;•the “JOBS Act” refer to the Jumpstart Our Business Startups Act of 2012;•the “Securities Act” refer to the Securities Act of 1933, as amended;•the “Exchange Act” refer to the Securities Exchange Act of 1934, as amended; and•the “SEC” refer to the Securities and Exchange Commission.iTable of ContentsAbout This ProspectusWe and the underwriters have not authorized anyone to provide any information other than that contained in this prospectus or in any free
Our strategy encompasses the following key elements:•Develop and advance our pipeline of Probody cancer immunotherapies directed against clinically-validated targets.•Develop and advance our pipeline of first-in-class Probody cancer therapies directed against novel targets.•Establish collaborations on selected programs with leading biopharmaceutical companies while retaining significant ownership of our pipeline.•Maximize value creation by advancing our lead product candidates to commercialization, by ourselves or with partners.•Maintain our competitive advantage by continuing to invest in our Probody platform for the long term.•Nurture and reinforce our company’s culture and core values to drive the highest levels of performance and continue to attract the best talent.Risks Related to Our BusinessOur ability to implement our current business strategy is subject to numerous risks, as more fully described in the section entitled
net losses for the foreseeable future as we continue development of, and seek regulatory approvals for, our product candidates.5Table of Contents•Even if we consummate this offering, we will need to raise additional funds to support our operations.
business, financial condition, results of operations and prospects may be materially and adversely affected.•Our approach to the discovery and development of innovative therapeutic treatments based on novel technologies is unproven and may not result in products with commercial value.•If clinical trials of our product candidates fail to demonstrate safety and efficacy, we may be unable to obtain regulatory approvals and commercialize our product candidates.•We are subject to regulatory approval processes that are lengthy, time-consuming and unpredictable.
less than we anticipate.•It is difficult and costly to protect our intellectual property rights.•We may face competition from other companies in our field or claims from third parties alleging infringement of their intellectual property.•We may be unable to recruit or retain key employees, including members of our senior management team.•We depend on the performance of third parties, including contract research organizations (“CROs”) and third-party manufacturers.Biopharmaceutical product development, particularly in the field of oncology, is a highly speculative undertaking and involves a substantial
We do not currently have any product candidates in clinical trials or approved for sale, and we continue to incur significant research and development and general and administrative expenses related to our operations.
losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.We are a preclinical stage biopharmaceutical company with a limited operating history, developing a novel class of therapeutic antibody
The timing and amount of our operating expenditures will depend largely on:•the timing and progress of preclinical and clinical development activities;•the number and scope of preclinical and clinical programs we decide to pursue;•the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and development agreements;•the timing and amount of milestone payments we may receive under our collaborations agreements;•our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements;•the costs involved in prosecuting and enforcing patent and other intellectual property claims;•the cost and timing of regulatory approvals; and•our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and
modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:•negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or
clinical trials or abandon a program;•product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates;•delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial
once commenced;•conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;•delays in enrolling research subjects in clinical trials;•high drop-out rates of research subjects;•inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;•greater than anticipated clinical trial costs;•poor effectiveness of our product candidates during clinical trials;•unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;•failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;•delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or•varying interpretations of data by the FDA and similar foreign regulatory agencies.Our approach to the
Market acceptance of our product candidates will depend on, among other factors:•the timing of our receipt of any marketing and commercialization approvals;15Table of Contents•the terms of any approvals and the countries in which approvals are obtained;•the safety and efficacy of our product candidates;•the prevalence and severity of any adverse side effects associated with our product candidates;•limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;•relative convenience and ease of administration of our product candidates;•the willingness of patients to accept any new methods of administration;•the success of our physician education programs;•the availability of adequate government and third-party payor reimbursement;•the pricing of our products, particularly as compared to alternative treatments; and•availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business,
Our or a third party’s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:•an inability to initiate or continue clinical trials of product candidates under development;•delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;•loss of the cooperation of an existing or future collaborator;•subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;•requirements to cease distribution or to recall batches of our product candidates; and•in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.19Table of ContentsWe, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product
breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.Our research, development and manufacturing involves the use of hazardous materials and various chemicals.
addition, there can be no assurance that:•Others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license.•We or our licensors, or our existing or future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license.•We or our licensors, or our existing or future collaborators are the first to file patent applications covering certain aspects of our inventions.26Table of Contents•Others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.•A third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed.•Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties.•We may develop additional proprietary technologies that are patentable.•The patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects.•Our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products